drugset / Trial / NCT04944979
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).
Timeline
- Start
- 2021-03-31
- Primary completion
- 2026-12
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Kedrion IVIG | Protein / enzyme biologic | 200 mg/kg | Intravenous |
| Subject | Kedrion IVIG | Protein / enzyme biologic | 800 mg/kg | Intravenous |